n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, May 25th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Nutra Pharma Corp. (NPHC)

Innovative Marketing, StocksToBuyNow, PennyStocks24, SeriousTraders, Streetwise Reports, MyBestStockAlerts, BUYINS.NET, UndiscoveredEquities, Pumps and Dumps, Wallstreetlivechat, and Winston Small Cap reported earlier on Nutra Pharma Corp. (NPHC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Nutra Pharma Corp. is a biotechnology company that lists on the OTC Markets Group’s OTCQB. The Company specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company is marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market.  Nutra Pharma has its corporate office in Coral Springs, Florida.

The emphasis of Nutra Pharma's approach to drug discovery and the development of new therapeutic agents is founded on specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. Its leading drug candidates are RPI-78M and RPI-MN.

The Company, by way of its subsidiaries, carries out basic drug discovery research and clinical development. Additionally, it looks for strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma’s holding, ReceptoPharm, is developing technologies to produce drugs for HIV and MS.

Nutra Pharma’s subsidiary, Designer Diagnostics, involves in the research and development (R&D) of diagnostic test kits designed to be used for the rapid identification of infectious diseases, including Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma offers several drug products for sale for pain treatment. One is Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Another is Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Nutra Pharma also has its Pet Pain-Away. This is the first OTC product to treat pain in companion animals without side effects.

Last year, Nutra Pharma announced a manufacturing alliance with Omnia Biologics. This alliance is to clone and produce alpha-cobratoxin to produce RPI-78M for upcoming clinical trials in Pediatric Multiple Sclerosis. Nutra Pharma's MS drug RPI-78M was recently granted Orphan Status by the Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis.

The Company’s RPI-MN inhibits the entry of many viruses known to cause severe neurological damage in diseases such as encephalitis and AIDS. RPI-MN is undergoing development initially for the treatment of HIV. Nutra Pharma’s RPI-78M is undergoing development for the treatment of multiple sclerosis (MS). RPI-78M can be administered orally, which is a first for a biologic MS drug.

RPI-78M and RPI-MN contain anticholinergic peptides, which recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process, unique to ReceptoPharm, the drugs are created via a process of chemical modification and possess many desirable properties as drugs.

Nutra Pharma Corp. (NPHC), closed Thursday's trading session at $0.0034, up 17.24%, on 5,235,290 volume with 48 trades. The average volume for the last 60 days is 5,715,923 and the stock's 52-week low/high is $0.0027/$0.019.

InterCloud Systems, Inc. (ICLD)

PennyPro, Promotion Stock Secrets, Marketbeat, Broad Street, StocksImpossible, OTCBB Journal, PennyStockProphet, Penny Pick Finders, Stock Onion, Planet Penny Stocks, Buzz Stocks, BUYINS.NET, Greenbackers, Jason Bond, RedChip, Wealthpire Inc., INO Market Report, GreatStockPix, Street Insider, Microcapmillionaires, Stock Tips Network, Hit and Run Candle Sticks, and Investing Futures reported on InterCloud Systems, Inc. (ICLD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

InterCloud Systems, Inc. is a foremost provider of cloud networking orchestration and automation solutions and services. It provides the modern-day Information Technology (IT) and network solutions to the enterprise markets via cloud computing and professional services. InterCloud offers cloud services (SaaS, PaaS, IaaS), professional consulting, data solutions, and maintenance services. InterCloud’s mission is to enable carriers to speed up the deployment of Virtualized Network and IT Services.  InterCloud Systems is based in Shrewsbury, New Jersey and the Company lists on the OTCQB.

InterCloud is a top provider of cloud networking orchestration and automation for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments to the telecommunications service provider (carrier) and corporate enterprise markets. The Company’s cloud solutions provide enterprise and service-provider customers the opportunity to adopt an operational expense model through outsourcing cloud deployment and management to InterCloud Systems.

InterCloud’s products and solutions include NFVGrid – NFVO Management & Analytics Platform. This is a full scale next generation networking platform for virtualized network functions. NFVGrid is proprietary Intellectual Property (IP). However, it fully embraces Open Source.

In late April, InterCloud Systems announced the sale of a majority interest in its AW Solutions, Inc. subsidiary.  AW Solutions provided DAS and Wi-Fi engineering services. Under the terms of the asset sale, InterCloud Systems will receive a $2.0 million convertible note in the new company, an additional working capital adjustment in 60 days, and a potential earnout after six months. Furthermore, the Company will retain a 19.9 percent ownership interest in the new company.

Last week, InterCloud Systems announced the sale of its Training Division. Its training division provided professional services centered on education and training in the network space. The asset was originally acquired by the Company in 2016 for $1.0 million in common stock.  Under the terms of the asset sale, InterCloud Systems received $1.4 million in cash, additional working capital adjustment, and the elimination of roughly $215,000 in net accrued liabilities.

InterCloud Systems, Inc. (ICLD), closed Thursday's trading session at $0.0205, up 1.99%, on 3,405,458 volume with 123 trades. The average volume for the last 60 days is 37,436,880 and the stock's 52-week low/high is $0.01/$1.14.

Agritek Holdings, Inc. (AGTK)

Promotion Stock Secrets, SmallCapVoice, CFN Media Group, PennyPro, and Cannabis Financial Network News reported earlier on Agritek Holdings, Inc. (AGTK), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Agritek Holdings, Inc. is a fully integrated, active cannabis real estate investor and branding consultant in the legal cannabis sector. The Company provides unique technology, brands, and agricultural solutions for the medicinal and recreational cannabis industry. At present, Agritek owns or manages property in Colorado, Puerto Rico, and Canada. It has licenses with permitted facilities in California approved for cultivation and manufacturing capabilities. Agritek Holdings’ shares trade on the OTC Markets’ OTCQB. Established in 2010, the Company is based in Miami, Florida, and has a satellite office in San Juan, Puerto Rico

The Company does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act. It does not intend to do so in the future. Agritek’s total holdings include two Royalty Agreements; two Equity Investments; seven Licensing Deals, and four Convertible Debentures. The Company’s solution is an integrated platform designed for commercialization in three high-value segments of the international cannabis market – Real Estate, AGTK Brands/IP, and Infrastructure.

The Company’s Colorado property is 80-Acres approved for cannabis cultivation or manufacturing facility situated in Pueblo, Colorado. Its Puerto Rico property is a 25,000-sq. ft. licensed cannabis cultivation and manufacturing facility. Agritek’s Canada property is a cannabis friendly "Bud & Breakfast" concept. It is one 1-hour from Quebec City and about a 2-hour flight from New York City. It is on 15-acres, which includes nine guest rooms plus a separate detached grow facility.

The Company’s brands are a premium positioned set of consumer brands for medical wellness and recreational use. Agritek owns a number of hemp and cannabis brands for distribution. These include MD Vapes, MicroDose Strips, "Hemp Pops" and "California Premiums."

In April, Agritek Holdings announced that it completed and fully executed a five-year operational and exclusive licensing agreement with a 25,000-sq. ft. and one of the largest approved cultivation facilities in San Juan, Puerto Rico. The Company will be the exclusive funding source, and supervise all infrastructure buildout, equipment lease/finance, security systems and personnel and provide access of experienced Colorado and California cultivation crews to ensure the facility meets all standard operating procedures as set forth by the Department of Health of Puerto Rico.

With this five year operational contract and licensing agreement, Agritek will receive revenue in the form of property rent, licensing fees on all vaporizer and edible brands, equipment and lighting rental and financing fees along with equity interest in the property.

This month, Agritek Holdings announced its first order for its licensed brand "MicroDose" Oral Strips for the medicinal market of California. The Company will provide the licensing and packaging to produce the exclusive line of 10mg and 50 mg oral strips as a medicinal alternative for patients. The Agritek "Microdose" brand will be produced and distributed via its permitted manufacturer and collective to numerous dispensaries across California. Agritek will receive a flat fee per single package designed exclusively by the Company with the first 10,000 units being delivered in June.

Agritek Holdings, Inc. (AGTK), closed Thursday's trading session at $0.0115, up 21.05%, on 22,964 volume with 40 trades. The average volume for the last 60 days is 7,234 and the stock's 52-week low/high is $1.71/$4.35.

Elite Pharmaceuticals, Inc. (ELTP)

Marketbeat, Promotion Stock Secrets, Pennybuster, PennyStocks24, TopPennyStockMovers, SmallCapVoice, Top Stock Picks, and Stock Analyzer reported earlier on Elite Pharmaceuticals, Inc. (ELTP), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. The Company is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products.  Elite specializes in oral sustained and controlled release drug products that have high barriers to entry. A specialty pharmaceutical company, Elite Pharmaceuticals is headquartered in Northvale, New Jersey, where it operates a GMP and DEA registered facility for research, development, and manufacturing.

Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite owns generic and Over-the Counter (OTC) products that have been licensed to TAGI Pharma, Epic Pharma, and Valeant Pharmaceuticals International. At present, Elite Pharmaceuticals has eight commercial products selling, additional approved products pending manufacturing site transfer, and the NDA for SequestOx™, for which it has received the CRL from the Food and Drug Administration (FDA).

Elite’s lead pipeline products include abuse-deterrent opioids, which use its patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.

Concerning the Company’s proprietary abuse-deterrent technology, ART™, it is a multi-particulate capsule that contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When the product is taken as intended, the design of naltrexone is to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed.

Recently, Elite Pharmaceuticals announced that it initiated pharmacokinetic testing of its reformulated SequestOx™. The expectation is that the reformulated product will have a shorter Tmax under fed conditions. The Company is conducting a bioequivalence study that is a pivotal, open-label, randomized, single-dose, three-way, crossover study to evaluate the relative comparative bioavailability and bioequivalence of the modified formulation of SequestOx™ to the original formulation of SequestOx™ and to a comparator product under fed conditions. The study has enrolled 45 healthy volunteers - the first subjects have been dosed.

Last month, Elite Pharmaceuticals announced that it filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of a synthetic narcotic analgesic indicated for the management of pain. The branded product and its equivalents had yearly sales of more than $40 million in 2016 according to IMS Health data.

Nasrat Hakim, Elite Pharmaceuticals’ President and Chief Executive Officer, said, “With the filing of this ANDA, Elite has three pain product ANDAs under review by the FDA. The market for these products has combined annual sales of over $1 billion. Elite continues developing new generics to grow its business.”

Elite Pharmaceuticals, Inc. (ELTP), closed Thursday's trading session at $0.177, down 12.81%, on 3,549,374 volume with 344 trades. The average volume for the last 60 days is 946,801 and the stock's 52-week low/high is $0.11/$0.395.

MyDx, Inc. (MYDX)

Promotion Stock Secrets, CFN Media Group, Cannabis Financial Network News, Cabot Wealth, SmallCap Network, and Greenbackers reported on MyDx, Inc. (MYDX), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

A science and technology company, MyDx, Inc. is the creator of MyDx® (My Diagnostic). This is the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to compare the chemical profile of cannabis with how it makes them feel and which ailments it alleviates. This product analyzes foods, drinks, and air for chemicals of interest. MyDx is headquartered in San Diego, California.

MyDx® is a patented, affordable portable analyzer. It provides real-time chemical analysis and fits in the palm of one’s hand. This device enables one to place a sample in a test chamber and see a total chemical analysis in a smartphone application (app). MyDx also offers the MyDx App. This app provides the user with more information to understand the chemicals found by the MyDx Analyzer.

MyDx owns a considerable and growing intellectual property (IP) portfolio of patents encompassing its technology. The MyDx AquaDx®, OrganaDx™ and CannaDx™ sensors are now commercialized. The AeroDx® application is next in line. All sensors will be compatible with a MyDx App.

MyDx is the first battery operated, handheld, electronic analyzer for consumers. MyDx employs nanotechnology to accurately measure chemicals of interest and has multiple sensors undergoing development in its lab, which are compatible with the MyDx App. A user connects the MyDx™ to their iOS, Android or Windows device. They subsequently place a sample in the chamber and push measure for an in-depth analysis of their sample within seconds.

The CannaDx™ sensor allows one to test their cannabis potency (% THC) on site and within a matter of minutes. This proprietary sensor also detects other cannabinoids (including CBD and CBN) and 20-plus terpenes. This provides one with a Total Canna Profile™ (TCP) – or a complete chemical analysis of their cannabis.

The OrganaDx™ sensor will first test for the most common pesticides linked to cancer. The AquaDx™ sensor will test for contaminants found in drinking water. The AeroDx™ sensor will measure elements of the E.P.A. (Environmental Protection Agency) air quality index through monitoring certain chemicals in the air.

Last month, MyDx announced its plans to develop and launch its second smart device (with associate engineering and prototype images) out of its Consumer Products Division for the Cannabis industry - the ECO Smart Pen™. The ECO Smart Pen™ is powered by MyDx. It is a next generation, rechargeable vaporizer pen equipped with Bluetooth technology, which helps patients and consumers better manage and regulate their cannabis consumption habits.

This month, MyDx announced a suite of upgrades to its MyDx 1.0 chemical analyzer hardware and software. The upgrades will significantly advance existing capabilities, including improvement in the overall performance of the device. Also, for the first time, these upgrades will allow the first of three anticipated upcoming sensor releases in AeroDx that will measure important air quality parameters for cannabis and non-cannabis consumers, to be interchanged seamlessly with the CannaDx Sensors.

MyDx, Inc. (MYDX), closed Thursday's trading session at $0.0091, up 1.56%, on 13,175,564 volume with 207 trades. The average volume for the last 60 days is 63,016,540 and the stock's 52-week low/high is $0.001/$0.225.

graphic

The QualityStocks
Company Corner

graphic
graphic

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.20, up 0.92%, on 22,964 volume with 40 trades. The stock’s average daily volume over the past 60 days is 7,234, and its 52-week low/high is $1.71/$4.35.

Monaker Group, Inc. has launched NextTrip, a new travel website and companion mobile app featuring instant Alternative Lodging Rentals (ALRs). The new releases of the NextTrip mobile app for iOS and Android are available for download today. NextTrip is the first travel service to offer all its ALR properties as instantly bookable. Now travelers can book private vacation homes, villas, chalets, apartments, condos and castles in combination with other major travel services, from conventional lodging and airlines to car rentals and tour packages.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Launches NextTrip Website and Mobile App Featuring 1.2 Million Instantly Bookable Vacation Rental Properties

Monaker Reports Fiscal 2017 Year-in-Review, Highlighting Travel Industry's First Instant Booking, Customizable Alternative Lodging Booking Engine

Monaker Group to Attend the Oppenheimer Emerging Growth Conference in New York City on May 16th

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0297, off by 1.00%, on 3,397,493 volume with 191 trades. The stock’s average daily volume over the past 60 days is 3,873,452, and its 52-week low/high is $0.0062/$0.142.

Singlepoint, Inc. NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is entitled, "Evolution of Marijuana Industry Creates Wealth of Opportunity for Companies with Foresight and Action." The article shines a light on businesses that provide innovative offerings in the consumer and commercial markets of the marijuana industry. To view the full publication, visit: https://www.networknewswire.com/evolution-marijuana-industry-creates-wealth-opportunity-companies-foresight-action/

Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.

SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.

SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.

As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication on Several Stocks Applying Their Innovations to the Evolving Marijuana Industry

SinglePoint Acquires 90% of DIGS an Online, Retail and Cannabis Consulting Company

SinglePoint Continues Acquisition Strategy with New LOI -- CFN Media

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.7903, up 2.64%,on 144,370 volume with 78 trades. The stock’s average daily volume over the past 60 days is 73,781 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com, Inc. Announces its New Subsidiary Chinesehempoil.com, Inc. and the Launch of its First Premium Hemp Health Product Line 'OptHemp'

ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report

ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.475, up 19.11%, on 400 volume with 2 trades. The stock’s average daily volume over the past 60 days is 4,031, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Signs Binding Letter of Intent to Acquire W Marketing

ProBility Media Corp. Expands Distribution with New 2017 Electrician Exam Preparation Series

ProBility Media Corp. Appoints Billy Smith to the Newly Created Vocational Advisory Board

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.4021, off by 1.33%, on 66,225 volume with 245 trades. The stock’s average daily volume over the past 60 days is 335,673, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

NetworkNewsWire Announces Editorial Discussing the Potential of Cannabis-Based Therapies for Pain Management

IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis-Based, Combination Therapies

IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

PennyStockProphet
(PTLF) +74.46%

2.

Wall Street Mover
(SDEV) +37.60%

3.

Wolf of Penny Stocks
(DCLT) +35.71%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251